Creative Medical Technology Holdings Provides Corporate Update
Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain
Strong Financial Position with No Long-Term Debt
PHOENIX, Nov. 15, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided an update on recent business activities in connection with the filing of its Form 10-Q with the Securities and Exchange Commission.
Related news for (CELZ)
- Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain
- 24/7 Market News Snapshot 13 August, 2025 – Creative Medical Technology Holdings, Inc. Common Stock (NASDAQ:CELZ)
- Today’s Top Performers: MoBot’s Market Review 07/09/25 03:00 PM
- Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds